Opioid Metabolites
- 1 May 2005
- journal article
- review article
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 29 (5), 10-24
- https://doi.org/10.1016/j.jpainsymman.2005.01.004
Abstract
No abstract availableKeywords
This publication has 86 references indexed in Scilit:
- Contribution of Morphine‐6‐Glucuronide to Antinociception following Intravenous Administration of Morphine to Healthy VolunteersThe Journal of Clinical Pharmacology, 2002
- Hydromorphone-3-glucuronideLife Sciences, 2001
- Morphine-6-GlucuronideClinical Pharmacokinetics, 2001
- Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatientsJournal of Pain and Symptom Management, 1997
- Acute neurotoxicity of meperidine in an infantPediatric Neurology, 1996
- Lack of morphi-ne-6-glucuronide antinociception after morphine treatment Is morphine-3-glucuronide involved?Pain, 1996
- Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypesLife Sciences, 1995
- The excitatory effects of morphine-3-glucuronide are attenuated by LY274614, a competitive NMDA receptor antagonist, and by midazolam, an agonist at the benzodiazepine site on the GABAA receptor complexLife Sciences, 1994
- Morphine Pharmacokinetics and Metabolism in HumansClinical Pharmacokinetics, 1993
- Morphine-6-glucuronide: Analgesic effects and receptor binding profile in ratsLife Sciences, 1988